Cargando…
Upcoming immunotherapeutic combinations for B-cell lymphoma
After initial introduction for B-cell lymphomas as adjuvant therapies to established cancer treatments, immune checkpoint inhibitors and other immunotherapies are now integrated in mainstream regimens, both in adult and pediatric patients. We here provide an overview of the current status of combina...
Autores principales: | Greve, Patrick, Meyer-Wentrup, Friederike A G, Peperzak, Victor, Boes, Marianne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326875/ https://www.ncbi.nlm.nih.gov/pubmed/35919738 http://dx.doi.org/10.1093/immadv/ltab001 |
Ejemplares similares
-
TIGIT-based immunotherapeutics in lung cancer
por: Patel, Akshay J, et al.
Publicado: (2023) -
Beyond Ipilimumab: a review of immunotherapeutic approaches in clinical trials in melanoma
por: Middleton, Gary
Publicado: (2020) -
The MARVEL trial: a phase 2b randomised placebo-controlled trial of oral MitoQ in moderate ulcerative colitis
por: Gwyer Findlay, Emily, et al.
Publicado: (2020) -
An overview of CAR T-cell clinical trial activity to 2021
por: Adami, Antonella, et al.
Publicado: (2021) -
A glutamine ‘tug-of-war’: targets to manipulate glutamine metabolism for cancer immunotherapy
por: Pallett, Laura J, et al.
Publicado: (2021)